Pharmaceutical utilisation and costs before and after bariatric surgery

Area of Science:

• Bariatric surgery outcomes
• Health economics
• Pharmaceutical utilization

Background:

• Obesity is a major public health concern associated with numerous comorbidities.
• Bariatric surgery is an effective treatment for obesity, but its impact on long-term pharmaceutical use and costs is not fully understood.
• Laparoscopic adjustable gastric banding (LAGB) is a common bariatric procedure.

Purpose of the Study:

• To evaluate changes in pharmaceutical utilization and associated costs following LAGB surgery.
• To assess the real-world impact of LAGB on medication use for obesity-related conditions and post-surgical management.

Main Methods:

• A retrospective analysis of 9542 Australians who underwent LAGB in 2007.
• Data linkage with Medicare, Australia's universal health insurance scheme.
• Comparison of pharmaceutical prescriptions across therapeutic categories from the year before surgery (2006) to two years after (2009) using incidence rate ratios (IRRs).

Main Results:

• Overall pharmaceutical utilization decreased from 10.5 to 9.6 prescriptions per person/year.
• Mean annual pharmaceutical costs reduced from $AUD517 to $AUD435 per person.
• Significant reductions were observed in diabetes (IRR 0.51), cardiovascular (IRR 0.81), and asthma (IRR 0.78) medications.
• Increased utilization was noted for pain (IRR 1.28) and gastrointestinal (IRR 1.04) medications.

Conclusions:

• LAGB surgery leads to a significant reduction in overall pharmaceutical utilization and costs in a real-world setting.
• The greatest absolute cost savings were achieved in medications for diabetes and cardiovascular diseases.
• Bariatric surgery demonstrates a positive impact on reducing medication burden for obesity-related comorbidities.